{"id":7703,"date":"2011-09-29T00:00:00","date_gmt":"2011-09-28T22:00:00","guid":{"rendered":"https:\/\/irb.usi.ch\/uncategorized\/eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees\/"},"modified":"2011-09-29T00:00:00","modified_gmt":"2011-09-28T22:00:00","slug":"eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees","status":"publish","type":"post","link":"https:\/\/irb.usi.ch\/it\/news\/eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees\/","title":{"rendered":"EU invests \u20ac30 million to boost vaccine research, the IRB is one of the 42 grantees"},"content":{"rendered":"

on<\/span> September 29, 2011<\/span><\/p>\n

On 1 October 2011 the collaborative research programme \u2013 Advanced Immunization Technologies (ADITEC) – will start in order to accelerate the development of novel and powerful immunization technologies for the next generation of human vaccines.  ADITEC is co-funded with \u20ac30M by the European Commission to establish a robust platform for innovation in this key strategic area with a high socio-economic impact. Scientists from 42 research partners in 13 countries will collaborate in this new programme.<\/strong><\/p>\n

Three groups from the IRB are among the 42 research partners involved in the ADITEC project. Using the high-throughput technologies, developed at the IRB, the groups of Prof. Lanzavecchia and Dr.Sallusto will identify the key mechanisms of the memory T-cell and B-cell responses involved in immune protection. Complementarily, the group of Dr. Uguccioni will study the expression and activity of key molecules (such as chemokines, cytokines and their receptors) which orchestrate the cell migration at mucosal sites. These combined researches will contribute to elucidate the mechanisms involved in mucosal immunity with the final aim of designing new immunization strategies.<\/p>\n

\u201cWe are at a unique point in vaccine history,\u201d says Rino Rappuoli, coordinator of ADITEC and president of the Sclavo Vaccines Association (SVA) which is based in Siena \/Italy. \u201cProgress in science and technology makes it possible to achieve what was previously deemed impossible. New technologies are opening the door to fight those diseases for which new vaccines could not be developed so far. However, a single laboratory cannot tackle modern vaccine science in isolation. Therefore we have set up this project consortium with scientists from 42 research bodies to collaboratively produce the knowledge necessary for the development of novel and powerful immunization technologies for the next generation of human vaccines.\u201d<\/p>\n

ADITEC comprises a team of competitive European universities and research institutions next to top US groups on systems biology and adjuvants. The project is reinforced by a number of key European industries, both big pharmaceutical and smaller biotechnology companies -these corporations are focusing on specific innovative technologies that now allow making better and safer vaccines-. In addition, the World Health Organization is supporting the project as a senior partner, ensuring that cross-cutting global health aspects are duly considered.<\/p>\n

From basic research to public health<\/strong><\/p>\n

This research programme covers a wide range of crucial aspects of vaccination; from basic research or new technologies to clinical trials and public health. The high impact project will therefore lead to: improved potency and safety of vaccines and their components, novel routes and devices of administration, optimized vaccination strategies, optimized formulations and vaccination methods for different age groups, better insight in the effects of gender, chronic diseases and genetic variation on vaccination and widespread knowledge about the available new technologies.<\/p>\n

Details of ADITEC project<\/strong><\/p>\n

Start date: 01\/10\/2011
\n\tEnd date: 30\/09\/2016
\n\tProject cost: \u20ac41 million
\n\tEU contribution: \u20ac30 million
\n\tCoordinator: Rino Rappuoli & Donata Medaglini, Sclavo Vaccines Association (SVA), Siena (Italy), email: info@associazionesclavo.org<\/a>, Tel: + 39-0577-233307
\n\t <\/p>\n

Participants<\/strong><\/p>\n

Sclavo Vaccines Association, Italy<\/p>\n

Statens Serum Institut, Denmark<\/p>\n

St George University of London, United Kingdom<\/p>\n

Max Planck Institute for Infection Biology, Germany<\/p>\n

University of Siena, Italy<\/p>\n

Institute Pasteur, France<\/p>\n

University of Oxford, United Kingdom<\/p>\n

University of Geneva, Switzerland<\/p>\n

Novartis Vaccines and Diagnostics s.r.l., Italy<\/p>\n

Intercell, Austria<\/p>\n

University of Gothenburg, Sweden<\/p>\n

Leiden University and Medical Centre, The Netherlands<\/p>\n

Emory University Atlanta, USA<\/p>\n

Tuberculosis Vaccine Initiative, The Netherlands<\/p>\n

Institute for Biomedical Aging Research of the Austrian Academy of Sciences, Austria<\/p>\n

Infectious Disease Research Institute Seattle, USA<\/p>\n

Utrecht University, The Netherlands<\/p>\n

Fondazione Humanitas per la Ricerca, Italy<\/p>\n

Fondazione per l\u2019Istituto di Ricerca in Biomedicina, Switzerland<\/p>\n

Istituto Superiore di Sanit\u00e0, Italy<\/p>\n

Kings College London, United Kingdom<\/p>\n

World Health Organization, Switzerland<\/p>\n

French Atomic Energy, France<\/p>\n

Institut de Biologie et Chimie des Prot\u00e9ines, France<\/p>\n

Erasmus Medical Center, The Netherlands<\/p>\n

ALTA s.r.l.u, Italy<\/p>\n

Medicine in need, France<\/p>\n

deCODE Genetics, Iceland<\/p>\n

Okairos, Italy<\/p>\n

Sigmoid Pharma, Ireland<\/p>\n

Vaccibody, Norway<\/p>\n

Pevion Biotech, Switzerland<\/p>\n

Duotol AB, Sweden<\/p>\n

Crossbeta Biosciences, The Netherlands<\/p>\n

Microbiotecsrl, Italy<\/p>\n

ArenaVax, Switzerland<\/p>\n

Xbrane Bioscience AB, Sweden<\/p>\n

Bioneedle Group, The Netherlands<\/p>\n

Novartis Vaccines Institute for Global Health s.r.l, Italy<\/p>\n

National Institute for Biological Standards and Control, United Kingdom<\/p>\n

Seattle Biomedical Research Institute, USA<\/p>\n

Imperial College London, UK<\/p>\n","protected":false},"excerpt":{"rendered":"

on September 29, 2011 On 1 October 2011 the collaborative research programme \u2013 Advanced Immunization Technologies (ADITEC) – will start in order to accelerate the development of novel and powerful immunization technologies for the next generation of human vaccines.  ADITEC is co-funded with \u20ac30M by the European Commission to establish a robust platform for innovation […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[16],"tags":[],"yoast_head":"\nEU invests \u20ac30 million to boost vaccine research, the IRB is one of the 42 grantees - IRB USI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irb.usi.ch\/it\/news\/eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EU invests \u20ac30 million to boost vaccine research, the IRB is one of the 42 grantees - IRB USI\" \/>\n<meta property=\"og:description\" content=\"on September 29, 2011 On 1 October 2011 the collaborative research programme \u2013 Advanced Immunization Technologies (ADITEC) – will start in order to accelerate the development of novel and powerful immunization technologies for the next generation of human vaccines.  ADITEC is co-funded with \u20ac30M by the European Commission to establish a robust platform for innovation […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irb.usi.ch\/it\/news\/eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees\/\" \/>\n<meta property=\"og:site_name\" content=\"IRB USI\" \/>\n<meta property=\"article:published_time\" content=\"2011-09-28T22:00:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\">\n\t<meta name=\"twitter:data1\" content=\"3 minuti\">\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irb.usi.ch\/it\/#website\",\"url\":\"https:\/\/irb.usi.ch\/it\/\",\"name\":\"IRB USI\",\"description\":\"Institute for Research in Biomedicine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/irb.usi.ch\/it\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/it\/news\/eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees\/#webpage\",\"url\":\"https:\/\/irb.usi.ch\/it\/news\/eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees\/\",\"name\":\"EU invests \\u20ac30 million to boost vaccine research, the IRB is one of the 42 grantees - IRB USI\",\"isPartOf\":{\"@id\":\"https:\/\/irb.usi.ch\/it\/#website\"},\"datePublished\":\"2011-09-28T22:00:00+00:00\",\"dateModified\":\"2011-09-28T22:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/irb.usi.ch\/it\/#\/schema\/person\/c9b66c69925e1b0c558072acbadf4156\"},\"breadcrumb\":{\"@id\":\"https:\/\/irb.usi.ch\/it\/news\/eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irb.usi.ch\/it\/news\/eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irb.usi.ch\/it\/news\/eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/it\/\",\"url\":\"https:\/\/irb.usi.ch\/it\/\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"position\":2,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/.\/news\/\",\"url\":\"https:\/\/irb.usi.ch\/.\/news\/\",\"name\":\"News\"}},{\"@type\":\"ListItem\",\"position\":3,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/it\/news\/eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees\/\",\"url\":\"https:\/\/irb.usi.ch\/it\/news\/eu-invests-e30-million-to-boost-vaccine-research-the-irb-is-one-of-the-42-grantees\/\",\"name\":\"EU invests \\u20ac30 million to boost vaccine research, the IRB is one of the 42 grantees\"}}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/irb.usi.ch\/it\/#\/schema\/person\/c9b66c69925e1b0c558072acbadf4156\",\"name\":\"AD_Dave\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/posts\/7703"}],"collection":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/comments?post=7703"}],"version-history":[{"count":0,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/posts\/7703\/revisions"}],"wp:attachment":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/media?parent=7703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/categories?post=7703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/tags?post=7703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}